Grifols Management
Management criteria checks 2/4
Grifols' CEO is Nacho Abia Buenache, appointed in Apr 2024, has a tenure of 2.25 years. total yearly compensation is €3.52M, comprised of 56.9% salary and 43.1% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth €1.01M. The average tenure of the management team and the board of directors is 6 years and 4.1 years respectively.
Key information
Nacho Abia Buenache
Chief executive officer
€3.5m
Total compensation
| CEO salary percentage | 56.87% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 6yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
GRF: New Bleeding Disorder Therapy And Margin Focus Will Drive Future Upside
Analysts have trimmed their price target on Grifols by €0.25, reflecting slightly lower fair value assumptions and updated views on discount rates, growth, and profitability, in line with recent Street research that reduced targets by about €1.00. Analyst Commentary Recent research on Grifols points to a more cautious stance on valuation, with price targets adjusted to reflect updated assumptions on growth, profitability, and discount rates.Grifols (BME:GRF) Stock Could Be 37.9% Undervalued After FESILTY Launch
Grifols (BME:GRF) has drawn fresh attention after launching FESILTY in the U.S., a fibrinogen concentrate for acute bleeding in patients with congenital fibrinogen deficiency, following recent FDA approval and supporting clinical data. See our latest analysis for Grifols. For investors, the FESILTY launch comes at a time when Grifols’ 1 day share price return of 1.04% and 7 day share price return of 0.75% sit against a year to date share price return that has declined 18.70%, while the 1 year...
GRF: Margin Protection And Biopharma Strength Will Support Future Upside
Analysts have reduced their price target on Grifols to €10 from €11, reflecting updated views on revenue growth and margins, as well as recent resets in Street forecasts following concerns around albumin and alpha-1 trends. Analyst Commentary Recent Street research reflects a more cautious stance on Grifols, with price targets reset to €10 and €11 and ratings aligned with a more neutral view.GRF: Margin Protection And US Biopharma IPO Plans Will Drive Future Upside
Analysts have trimmed their fair value estimate for Grifols from €15.08 to €14.65. This reflects recent cuts to Street price targets and concerns around slower albumin and alpha-1 volume growth that have led banks such as Deutsche Bank and Morgan Stanley to lower their expectations.GRF: Higher Required Returns Will Still Support Upside From Current Pricing
Analysts have trimmed their price targets on Grifols, with recent research such as the move from €15.00 to €13.50 supporting a modest reduction in our fair value estimate from €15.20 to about €15.08. They are factoring in slightly softer growth and margin assumptions alongside a higher expected discount rate, partly offset by a higher future P/E ratio.GRF: Execution On Profitability Reset And Higher P/E Will Unlock Upside
Analysts have nudged their fair value estimate for Grifols slightly lower to €21.72 from €21.78, reflecting reduced revenue growth and profit margin assumptions, alongside a higher future P/E, in line with recent Street moves such as Barclays trimming its price target to €13.50 from €15.00. Analyst Commentary Bullish analysts appear to be treating the latest target cut as more of a valuation reset than a shift in long term conviction, with the rating held at Overweight even as the price objective moves to €13.50 from €15.00.GRF: Higher Required Returns Will Still Support Attractive Future Earnings Multiple
Analysts have trimmed their valuation outlook for Grifols, reducing the implied price target from €15.20 to €15.03 as they factor in a higher discount rate and a slightly richer future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: Held broadly steady at €15.20, with only a marginal adjustment to the implied price target in the updated model.GRF: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have modestly reduced their price target on Grifols from approximately 23.00 dollars to 21.78 dollars, citing a higher perceived discount rate that more than offsets slightly stronger long term revenue growth and margin assumptions, along with a lower future price to earnings multiple. What's in the News Grifols has scheduled a Board meeting on September 25, 2025, to approve the creation of a Strategy Committee with an advisory role focused on strategic initiatives and developments, as defined in the Regulations of the Internal Functioning of the Board of Directors and the committee's own regulations (company filing).GRF: Upcoming Strategy Committee Will Support Improved Profit Margins Ahead
Analysts have slightly lowered their price target for Grifols from $15.45 to $15.20, citing minor adjustments to growth projections and profit expectations. What's in the News Grifols, S.A. is holding a Board Meeting on September 25, 2025, to establish a Strategy Committee with an advisory role focused on strategic initiatives and developments (Key Developments).GRF: Rising Margins and Board Initiatives Will Drive Future Performance
Analysts have lowered their price target for Grifols from $16.48 to $15.45, citing modestly reduced revenue growth expectations and a lower future price-to-earnings multiple. This comes despite slightly improved profit margins and a more favorable discount rate.
Biopharma Innovations And Tactical Strengths Propel Future Profitability And Market Expansion
Grifols' focus on innovation and new product development is poised to drive future revenue growth and market expansion.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | €415m |
| Dec 31 2025 | €4m | €2m | €402m |
Compensation vs Market: Nacho's total compensation ($USD4.01M) is above average for companies of similar size in the Spanish market ($USD1.83M).
Compensation vs Earnings: Insufficient data to compare Nacho's compensation with company performance.
CEO
Nacho Abia Buenache (58 yo)
Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | €3.52m | 0.019% € 1.0m | |
| Chief Financial Officer | 1.8yrs | no data | 0.0015% € 81.0k | |
| Senior Vice President of Strategy & COO Office | no data | no data | no data | |
| Head of Investor Relations & Sustainability and Vice President | no data | no data | no data | |
| Chief Corporate Affairs & Legal Officer | 23.5yrs | no data | 0.0029% € 157.7k | |
| Chief Compliance Officer | 7.5yrs | no data | no data | |
| Chief Communications and Reputation Officer | 1.3yrs | no data | no data | |
| Chief Human Resources & Talent Officer | 2.4yrs | no data | no data | |
| Chief Quality Officer | 33.5yrs | no data | no data | |
| Chief Internal Audit & Enterprise Risk Manager | 4.5yrs | no data | no data | |
| President of Commercial Tech Support | 7.5yrs | no data | no data | |
| Chief Industrial Services Officer | 7.5yrs | no data | no data |
Experienced Management: GRF's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | €3.52m | 0.019% € 1.0m | |
| Independent Director | 11.2yrs | €164.00k | no data | |
| Chairman of Honour | no data | €129.00k | no data | |
| Independent Director | 1.6yrs | €129.00k | no data | |
| Member of the Advisory Committee | 11.5yrs | €380.00k | no data | |
| Vice-Chairman | 11.2yrs | €129.00k | 0.0063% € 335.7k | |
| Independent External Director | 26.3yrs | €129.00k | 0.044% € 2.4m | |
| Proprietary Director | 10.2yrs | €4.45m | 0.0063% € 335.7k | |
| Independent Chairman | 2.1yrs | €380.00k | no data | |
| Proprietary Director | 2.6yrs | €129.00k | 0.013% € 671.4k | |
| Independent Director | 4.1yrs | €164.00k | no data | |
| Independent Director | 4.1yrs | €154.00k | no data |
Experienced Board: GRF's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 17:37 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grifols, S.A. is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |